Mediabistro (MBIS) Skyrockets on Strategic Investment, Echo Therapeutics

Mediabistro Inc. (MBIS)

The price of MBIS ' stock skyrocketed after the company reported that it has made a strategic investment in the 3D printing media platform 3DPrintingIndustry.com (3DPI), a global media company providing dedicated resources for anyone interested in 3D printing — a technology field that is growing quickly in relevance and application across industrial and consumer sectors.

MBIS will not have editorial control of the content of the 3DPI portfolio, which will remain independent, but the two companies will work together to produce Inside 3D Printing trade shows along with the recently announced Maker Summit & Pavilion series that are being produced in major cities worldwide. In addition both companies will soon offer the first online job board for the 3D printing industry, powered by MBIS ' proprietary job board software.

MBIS is a leading Internet media company that provides services for social media, traditional media, and creative professionals, as well as for innovators in the 3D printing and mobile app industries. Service offerings include an online job board, news and analysis, trade shows and events, online and in-person courses, and research products.

More about Mediabistro Inc. (MBIS) at www.mediabistro.com

**

Echo Therapeutics, Inc. (ECTE)

Shares of ECTE soared on Tuesday's trading session after the company reported positive results from its multi-center clinical trial of the Symphony CGM System in surgical patients in hospital critical care units.

Data collected from this study will serve as the basis for the CE Mark Technical File submission for marketing approval in Europe, which ECTE expects to submit in the fourth quarter of 2013.

ECTE 's Symphony met the primary safety and effectiveness endpoints of the trial which involved the continuous monitoring of glucose levels in 32 subjects in the critical care units at four investigational sites.

In the trial, Symphony monitored glucose levels with a mean absolute relative difference (MARD), or error rate, of 12.5%. The Continuous Glucose-Error Grid Analysis (CG-EGA) showed that 97.9% of the readings were clinically accurate (A) and 1.8% were benign (B) errors with a combined A+B categorization of 99.7%.

ECTE is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the hospital critical care setting. Significant opportunity also exists for Symphony to be used in the hospital beyond the critical care setting. The Prelude(R) SkinPrep System, a component of the Symphony CGM System, allows for enhanced skin permeation that will enable extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.

More about at Echo Therapeutics, Inc. (ECTE) at www.echotx.com

**

Crown Equity Holdings Inc. (CRWE)

Forging new relationships between businesses is becoming critical for businesses to survive and blossom in this increasingly fast paced world. Business to Business (B2B) applications provide new opportunities for businesses to leverage emerging technologies to build their businesses. Examples of B2B applications include facilitating transactions for goods/services between companies, selling goods/services on the Internet to businesses, and supply chain integration.

Looking to deliver value for its stockholders in both the near and long term, CRWE is refocusing its strategic plan to improve the potential future growth for the company, targeting the multi-billion dollar online b2b market, with its ts iB2B Global project.

CRWE ‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. CRWE launches, invests and manages select businesses, projects and real estate endeavors.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .

**

Read Full Disclaimer at www.pennyomega.com/disclaimer